TransThera Sciences (Nanjing), Inc.
藥捷安康（南京）科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2617)

VOLUNTARY ANNOUNCEMENT

TransThera Sciences (Nanjing), Inc. and Shanghai Allist Pharmaceuticals Co., Ltd. Announce a Collaboration Agreement to Jointly Evaluate the Combination of TT-00973-MS Tablets with Firmonertinib Mesylate Tablets in the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR-Sensitive Mutations

This announcement is made by TransThera Sciences (Nanjing), Inc. (the "**Company**" or "**TransThera**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The Company is pleased to announce that the Company and Shanghai Allist Pharmaceuticals Co., Ltd. ("**Allist**") entered into a clinical trial collaboration and supply agreement. Both parties will jointly advance a multi-center, open-label Phase II study (the "**Clinical Trial**") to evaluate the safety and efficacy of TT-00973-MS tablets in combination with firmonertinib mesylate tablets in patients with locally advanced or metastatic non-small cell lung cancer with EGFR-sensitive mutations.

Under the terms of the agreement, TransThera, as the sponsor of the Clinical Trial, will be responsible for operation and costs of the Clinical Trial. Allist will provide firmonertinib mesylate tablets required for the Clinical Trial free of charge. Based on the results of the Clinical Trial, both parties will jointly explore collaboration opportunities for further conducting a Phase III clinical trial of the combination of TT-00973-MS tablets and firmonertinib mesylate tablets.

TT-00973 is a novel dual AXL/FLT3 inhibitor internally developed by the Company. AXL kinase is a key player in survival, metastasis, and drug resistance in cancer, and aberrant activation of AXL signaling is associated with poor prognosis in many types of cancers. TT-00973 is potent in abrogating AXL activation in tumor cells, and demonstrates effective antitumor activity in murine xenograft models with AXL overexpression. As of 31 December 2025, the Company has completed the Phase I clinical trial, in which TT-00973 was well tolerated and responses was observed in some patients with solid tumors.

Firmonertinib mesylate tablets are an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Clinical research results have shown that firmonertinib demonstrates broad efficacy against various EGFR mutations. Its indications for first-line treatment, first-line and second-line treatment of NSCLC with EGFR exon 20 insertion mutations, and first-line treatment of NSCLC with EGFR PACC mutations, have been successively included in the List of Breakthrough Therapy Designation (突破性治療品種名單) by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The indication for first-line treatment of NSCLC with EGFR exon 20 insertion mutations has also been granted the Breakthrough Therapy Designation (BTD) (突破性療法認定) by the U.S. Food and Drug Administration (FDA).

Warning under Rule 18A.08(3) of the Listing Rules: There is no assurance that the relevant products will ultimately be successfully developed and marketed by the Company.

By order of the Board
TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司
Dr. Frank Wu
Chairman and Chief Executive Officer

Hong Kong, May 26, 2026

As at the date of this announcement, the Board comprises: (i) Dr. Frank Wu and Mr. Wu Di as executive directors; (ii) Ms. Jia Zhongxin as a non-executive director; and (iii) Mr. Li Shu Pai, Ms. Chui Hoi Yam and Ms. Zheng Zhelan as independent non-executive directors.